Heterodimerization with the β 1 subunit directs the α 2 subunit of nitric oxide-sensitive guanylyl cyclase to calcium-insensitive cell-cell contacts in HEK293 cells: Interaction with Lin7a

Hochheiser, Julia; Haase, Tobias; Busker, Mareike; Sömmer, Anne; Kreienkamp, Hans‐Jürgen; Behrends, Sönke

doi:10.1016/j.bcp.2016.10.008

Cited by 4 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At this meeting, overexpressed NO-GC2 but not NO-GC1 was shown to be located at cell–cell contacts in HEK293 cells which implies a role in regulating cell adhesion and cell–cell contacts (Soenke Behrends, Braunschweig). A mutated form of NO-GC2 (carrying a mutation in the α2 subunit originally identified in a patient with lung adenocarcinoma) was overexpressed in HEK293 cells and found not to bind to cell–cell contacts (Hochheiser et al 2016 ). Loss of cell–cell contacts could interfere with NO-GC2’s signaling properties, which could affect cancerogenesis.…”

Section: Meeting Highlightsmentioning

confidence: 99%

The 10th International Conference on cGMP 2022: recent trends in cGMP research and development—meeting report

Friebe

Kraehling

Russwurm

et al. 2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Increasing cGMP is a unique therapeutic principle, and drugs inhibiting cGMP-degrading enzymes or stimulating cGMP production are approved for the treatment of various diseases such as erectile dysfunction, coronary artery disease, pulmonary hypertension, chronic heart failure, irritable bowel syndrome, or achondroplasia. In addition, cGMP-increasing therapies are preclinically profiled or in clinical development for quite a broad set of additional indications, e.g., neurodegenerative diseases or different forms of dementias, bone formation disorders, underlining the pivotal role of cGMP signaling pathways. The fundamental understanding of the signaling mediated by nitric oxide-sensitive (soluble) guanylyl cyclase and membrane-associated receptor (particulate) guanylyl cyclase at the molecular and cellular levels, as well as in vivo, especially in disease models, is a key prerequisite to fully exploit treatment opportunities and potential risks that could be associated with an excessive increase in cGMP. Furthermore, human genetic data and the clinical effects of cGMP-increasing drugs allow back-translation into basic research to further learn about signaling and treatment opportunities. The biannual international cGMP conference, launched nearly 20 years ago, brings all these aspects together as an established and important forum for all topics from basic science to clinical research and pivotal clinical trials. This review summarizes the contributions to the “10th cGMP Conference on cGMP Generators, Effectors and Therapeutic Implications,” which was held in Augsburg in 2022 but will also provide an overview of recent key achievements and activities in the field of cGMP research.

show abstract

Section: Meeting Highlightsmentioning

confidence: 99%